Zobrazeno 1 - 10
of 180
pro vyhledávání: '"Ricky A Sharma"'
Autor:
Tetsuo Akimoto, MD, Hidefumi Aoyama, MD, Melvin L.K. Chua, MBBS, FRCR, PhD, FAMS, Dasantha Jayamanne, MD, Takashi Mizowaki, MD, PhD, Lucinda Morris, MBBS, Hiroshi Onishi, MD, Si Yeol Song, MD, Youssef H. Zeidan, MD, PhD, Ricky A. Sharma, MA, MB, BChir, FRCP, FRCR, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 6, Pp 101291- (2023)
Hypofractionated radiotherapy schedules provide higher per-fraction radiation doses delivered in fewer fractions than conventional schedules. This novel delivery method is supported by a large body of clinical trial evidence across various cancer sit
Externí odkaz:
https://doaj.org/article/b78cce79a6e843f5863da9aea44e837b
Autor:
Maxime Dubail, Sophie Heinrich, Lucie Portier, Jessica Bastian, Lucia Giuliano, Lilia Aggar, Nathalie Berthault, José-Arturo Londoño-Vallejo, Marta Vilalta, Gael Boivin, Ricky A. Sharma, Marie Dutreix, Charles Fouillade
Publikováno v:
Cells, Vol 12, Iss 20, p 2435 (2023)
To rapidly assess healthy tissue toxicities induced by new anti-cancer therapies (i.e., radiation alone or in combination with drugs), there is a critical need for relevant and easy-to-use models. Consistent with the ethical desire to reduce the use
Externí odkaz:
https://doaj.org/article/ef3dbdb660124597aecf336248a066ab
Publikováno v:
Diagnostic and Interventional Radiology, Vol 27, Iss 5, Pp 677-683 (2021)
Colorectal cancer liver metastases (CRLMs) are common. Treating CRLMs with thermal ablation can prolong survival, but compared to lesions smaller than 3 cm, local control rates and overall survival are relatively worse with larger, intermediate (3–
Externí odkaz:
https://doaj.org/article/60a8d2c25a724e658ff19afe6a73a586
Autor:
Rebecca Carter, Azadeh Cheraghchi-Bashi, Adam Westhorpe, Sheng Yu, Yasmin Shanneik, Elena Seraia, Djamila Ouaret, Yasuhiro Inoue, Catherine Koch, Jenny Wilding, Daniel Ebner, Anderson J. Ryan, Francesca M. Buffa, Ricky A. Sharma
Publikováno v:
Cancer Biology & Medicine, Vol 16, Iss 2, Pp 234-246 (2019)
Objective Patients with BRAF-mutant colorectal cancer (CRC) have a poor prognosis. Molecular status is not currently used to select which drug to use in combination with radiotherapy. Our aim was to identify drugs that radiosensitise CRC cells with k
Externí odkaz:
https://doaj.org/article/20f6deba4d8f477f8d7767514aae6c9b
Autor:
Paul C. Lyon, BSc, MSc, MRCS, MRes, DPhil, Helen Winter, BSc, MBBS, MSc, MRCP, FRACP, Karin Herbschleb, MRCP, Leticia Campo, Diploma, Robert Carlisle, PhD, Feng Wu, MD, PhD, Robert Goldin, MD, MEd, FRCPath, Constantin C. Coussios, PhD, Mark R. Middleton, BA, MA, PhD, FRCP, Fergus V. Gleeson, FRCR, FRCP, Philip Boardman, FRCR, Ricky A. Sharma, MB, BChir, MA, PhD, FRCP, FRCR
Publikováno v:
Radiology Case Reports, Vol 13, Iss 6, Pp 1259-1266 (2018)
Liver metastasis from breast cancer is associated with poor prognosis and is a major cause of early morbidity and mortality. When liver resection is not feasible, minimally invasive directed therapies are considered to attempt to prolong survival. Se
Externí odkaz:
https://doaj.org/article/20f6dd12649d40dc90fb887054b18b43
Autor:
Veerle Kersemans, Ricky A. Sharma, Mike Partridge, Ruth J. Muschel, Adrian L. Harris, Tim Maughan, Julia A. Schnabel, Sean Smart, Stuart Gilchrist, Paul Kinchesh, Bosjtan Markelc, Jakob Kaeppler, Bartlomiej W. Papiez, Benjamin Irving, Nigar Syed, Philip D. Allen, Russell Bates, Daniel Warren, Helen Winter, Warren W. Kretzschmar, Pavitra Kannan
Purpose: Tumor vessels influence the growth and response of tumors to therapy. Imaging vascular changes in vivo using dynamic contrast-enhanced MRI (DCE-MRI) has shown potential to guide clinical decision making for treatment. However, quantitative M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8bf5abfae121c63556b55f9b40579c
https://doi.org/10.1158/1078-0432.c.6527586
https://doi.org/10.1158/1078-0432.c.6527586
Autor:
Ricky A. Sharma, Michael Partridge, William G. McKenna, Ruth Muschel, Phil Quirke, Julia A. Schnabel, Sharon B. Love, Susan Dutton, Gina Brown, Ewan M. Anderson, Somnath Mukherjee, Lai-Mun Wang, Claire Blesing, Lucy Boyle, Kwun-Ye Chu, Thomas P. MacGregor, Nicholas West, Monica Enescu, Jamie M. Franklin, Corran Roberts, Esme J. Hill
Purpose: Nelfinavir, a PI3K pathway inhibitor, is a radiosensitizer that increases tumor blood flow in preclinical models. We conducted an early-phase study to demonstrate the safety of nelfinavir combined with hypofractionated radiotherapy (RT) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d48be61bfbee8baea4bd21fb9afab1d
https://doi.org/10.1158/1078-0432.c.6524669
https://doi.org/10.1158/1078-0432.c.6524669
Autor:
Ricky A. Sharma, Michael Partridge, William G. McKenna, Ruth Muschel, Phil Quirke, Julia A. Schnabel, Sharon B. Love, Susan Dutton, Gina Brown, Ewan M. Anderson, Somnath Mukherjee, Lai-Mun Wang, Claire Blesing, Lucy Boyle, Kwun-Ye Chu, Thomas P. MacGregor, Nicholas West, Monica Enescu, Jamie M. Franklin, Corran Roberts, Esme J. Hill
Supplementary Table 1: Laboratory values (Liver Function Tests) Supplementary Table 2: Overview of mean pCT parameters for tumour VOI on sequential scans Supplementary Table 3: Overview of median DCE-MRI parameters, Ktrans, Ve and Kep for tumour VOI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d37adcd2427aeed26972cf2348585c1
https://doi.org/10.1158/1078-0432.22461002
https://doi.org/10.1158/1078-0432.22461002
Autor:
Veerle Kersemans, Ricky A. Sharma, Mike Partridge, Ruth J. Muschel, Adrian L. Harris, Tim Maughan, Julia A. Schnabel, Sean Smart, Stuart Gilchrist, Paul Kinchesh, Bosjtan Markelc, Jakob Kaeppler, Bartlomiej W. Papiez, Benjamin Irving, Nigar Syed, Philip D. Allen, Russell Bates, Daniel Warren, Helen Winter, Warren W. Kretzschmar, Pavitra Kannan
Supplementary methods and data. Supplementary Table 1. Equations of chosen models fit using ordinary least squares regression with the best Bayesian Information Criterion for iAUC90, Ktrans, and BATfrac in untreated preclinical tumors (cohort 1). Goo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57976c059b7a53d0abb5e6c056d2f328
https://doi.org/10.1158/1078-0432.22470495.v1
https://doi.org/10.1158/1078-0432.22470495.v1
Autor:
Thomas Helleday, Nicola J. Curtin, Sven Rottenberg, Ricky A. Sharma, Adrian L. Harris, Ariena Kersbergen, Evgenia Gubanova, Cecilia Lundin, Evan A. Mulligan, Vicky Chatzakos, Kate Sleeth, Rafal Zur, Ponnari Gottipati, Nicholas Pedley, Suzanne Kyle, Ivaylo Stoimenov, Janneke E. Jaspers, Tatjana Djurenovic, Huw D. Thomas, Natalia Issaeva
Supplementary Figure 3 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e67dc7b078b192391de4e70c66a94ca
https://doi.org/10.1158/0008-5472.22382102
https://doi.org/10.1158/0008-5472.22382102